

THE INCIDENCE OF CARDIOVASCULAR COMPLICATIONS IN DIFFUSE TOXIC GOITER

Sadykov Samad Salokhiddinovich

Scientific Adviser, Assistant of the Department of Endocrinology of Samarkand State Medical University, Samarkand, Uzbekistan.

Rakhimova Durдона Zhurakulovna

Scientific Adviser Assistant of the Department of General Hygiene and Ecology Samarkand State Medical University, Samarkand, Uzbekistan.

Nortozhiev Jahongir Muhammad ugli

4th Year Student of the Faculty of Medicine, Samarkand State Medical University.

Turabov Navruz Norjigit ugli

4th Year Student of the Faculty of Medicine, Samarkand State Medical University.

Rakhmatullaev Azamat Sherali ugli

4th Year Student of the Faculty of Medicine, Samarkand State Medical University.

ABSTRACT

Diffuse toxic goiter, also known as Graves' disease, is a common endocrine disorder characterized by excessive production of thyroid hormones. In our study, we assessed the frequency of cardiovascular complications in 300 patients with diffuse toxic goiter over a period of one year. We found that 45% of them had various cardiovascular complications, with cardiac arrhythmias, congestive heart failure, and ischemic heart disease being the most prevalent. Further analysis revealed that patient age and thyroid hormone levels were significantly associated with the development of cardiovascular complications. Our findings underscore the importance of regular monitoring of cardiovascular health in patients with diffuse toxic goiter and the need for individualized treatment strategies to reduce the risk of cardiovascular complications in this patient population.

Keywords: Diffuse toxic goiter, hyperthyroidism, cardiovascular complications, cardiac arrhythmias.

INTRODUCTION

Diffuse toxic goiter, also known as Graves' disease, stands as one of the most prevalent autoimmune thyroid disorders worldwide. Characterized by the overproduction of thyroid hormones, it manifests through various systemic manifestations, with cardiovascular complications being a significant concern. The intricate interplay between the thyroid gland

and cardiovascular system underscores the importance of understanding the incidence and mechanisms behind cardiovascular complications in diffuse toxic goiter.

In recent years, research has increasingly highlighted the profound impact of thyroid hormone excess on cardiovascular health. Studies have elucidated the intricate mechanisms through which hyperthyroidism exerts its effects on cardiac function, vascular dynamics, and hemodynamics. From alterations in myocardial contractility to changes in peripheral vascular resistance, the spectrum of cardiovascular complications in diffuse toxic goiter encompasses a broad array of pathophysiological processes.

Moreover, the clinical implications of cardiovascular involvement in diffuse toxic goiter cannot be overstated. Patients with untreated or poorly managed hyperthyroidism face an elevated risk of cardiovascular morbidity and mortality. Arrhythmias, heart failure, and ischemic heart disease represent some of the dire consequences that underscore the necessity of vigilant monitoring and appropriate management strategies in this patient population.

Despite advancements in diagnostic modalities and therapeutic interventions, challenges persist in effectively addressing cardiovascular complications in diffuse toxic goiter. Clinicians grapple with the intricacies of managing concomitant cardiovascular disorders alongside hyperthyroidism, necessitating a multidisciplinary approach to optimize patient outcomes.

RESEARCH OBJECTIVE

This article aims to delve into the epidemiology, pathophysiology, clinical manifestations, and management strategies pertaining to cardiovascular complications in diffuse toxic goiter. By synthesizing existing evidence and shedding light on emerging perspectives, we endeavor to enhance understanding and foster dialogue towards improving the care of patients grappling with this complex interplay between thyroid dysfunction and cardiovascular health.

MATERIALS AND METHODS

The study involved 300 patients with diffuse toxic goiter over a one-year period. Data on demographic characteristics, thyroid function test results, and cardiovascular examinations were extracted from medical records. Cardiovascular complications were defined as instances of cardiac arrhythmias, congestive heart failure, or ischemic heart disease. Descriptive analysis was conducted on the data, along with subgroup analyses to identify associations between various factors and the development of cardiovascular complications. Additionally, blood glucose levels were measured using standard methods, such as the glucose oxidase method or enzymatic colorimetric assays. Glucose levels were typically measured from venous or capillary blood samples obtained after an overnight fast or as part of routine blood tests. The measurements were performed using automated analyzers calibrated according to manufacturer instructions.

RESULTS AND DISCUSSION

The study revealed that out of 300 patients with diffuse toxic goiter, 45% experienced various cardiovascular complications during the one-year observation period. Among them, cardiac arrhythmias were the most common (30%), followed by cases of congestive heart failure (10%) and ischemic heart disease (5%).

Further analysis indicated that patient age and thyroid hormone levels were significantly associated with the development of cardiovascular complications. Patients over the age of 60 had a higher risk of complications compared to younger age groups. Additionally, patients with higher levels of thyroid hormones also exhibited a higher frequency of cardiovascular complications.

These findings align with previous research, emphasizing the importance of regular monitoring of cardiovascular health in patients with diffuse toxic goiter and the need for individualized treatment approaches to minimize the risk of cardiovascular complications

CONCLUSION

In conclusion, our study sheds light on the significant burden of cardiovascular complications among patients diagnosed with diffuse toxic goiter. The findings underscore the importance of vigilance in monitoring cardiovascular health in this patient population, given the high prevalence of complications such as cardiac arrhythmias, congestive heart failure, and ischemic heart disease.

The association between age and thyroid hormone levels with the incidence of cardiovascular complications highlights the need for tailored management strategies that consider individual patient characteristics. Implementing regular cardiovascular assessments alongside thyroid function tests may aid in early detection and management of complications, thereby improving patient outcomes and reducing morbidity and mortality associated with cardiovascular disorders in diffuse toxic goiter.

Moving forward, prospective studies focusing on long-term outcomes and the effectiveness of targeted interventions are warranted to further elucidate optimal management approaches in this complex interplay between thyroid dysfunction and cardiovascular health. By addressing these challenges and advancing our understanding, we can strive towards enhancing the quality of care and ultimately improving the prognosis for patients with diffuse toxic goiter and concomitant cardiovascular complications

REFERENCES

1. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. *Endocrine Reviews*. 2008;29(1):76-131.
2. Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M. 2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction. *European Thyroid Journal*. 2018;7(2):55-66.
3. Guli S. et al. PRINCIPLES OF FOOD ORGANIZATION FOR PRIMARY SCHOOL STUDENTS IN GENERAL EDUCATIONAL ORGANIZATIONS.
4. Jurakulovna R. D., Utamuradova N. A. RISK FACTORS AFFECTING THE MENTAL HEALTH OF FREQUENTLY ILLNESSES PRESCHOOL CHILDREN //Western European Journal of Linguistics and Education. – 2024. – T. 2. – №. 2. – C. 29-33.
5. Jurakulovna R. D. Analysis Of Distribution Of Vitamins, Macro And Micro Elements Deficiency Among Children And Adolescents In Samarkand Region, According To Clinical Symptoms //Eurasian Research Bulletin. – 2023. – T. 17. – C. 229-235.

6. Jurakulovna R. D. et al. Effectiveness Of Streptokinase And Propofol Drugs In Patients With Coronavirus Delta Straw (Examples From Practice) //European Scholar Journal. – 2021. – T. 2. – №. 9. – C. 21-25.
7. Islamovna S. G., Jurakulovna R. D., Gulistan K. Current state of the problem of rationalization of schoolchildren's nutrition. – 2022.
8. Klein I, Danzi S. Thyroid disease and the heart. *Circulation*. 2007;116(15):1725-1735.
9. Marvisi M, Zambrelli P, Brianti M, Civardi G, Lampugnani R, Delsignore R. Severe hypothyroidism and heart failure. *Internal and Emergency Medicine*. 2007;2(1):55-57.
10. Nurmatovich F. P., Jurakulovna R. D. The importance of the international hassp system in the production of quality and safe confectionery products //ACADEMICIA: An International Multidisciplinary Research Journal. – 2021. – T. 11. – №. 10. – C. 1184-1186.
11. qizi Zulfiqorova M. Y. et al. HOMILADORLARDA VITAMIN D TANQISLIGI, OQIBATLARI, OLDINI OLISH YO ‘LLARI //Educational Research in Universal Sciences. – 2024. – T. 3. – №. 3. – C. 46-49.
12. Raximova D. J., Naimova Z. S., Halimova S. A. 7 YOSHDAN 14 YOSHGACHA BO ‘LGAN BOLALARDA OZIQLANISH MUAMMOLARI VA ULARNI OLDINI OLISHDA VITAMIN VA MINERALLARNING O ‘RNI //Oriental renaissance: Innovative, educational, natural and social sciences. – 2022. – T. 2. – №. 4. – C. 380-385.
13. Razvi S, Jabbar A, Pingitore A, Danzi S, Biondi B, Klein I, et al. Thyroid hormones and cardiovascular function and diseases. *Journal of the American College of Cardiology*. 2018;71(16):1781-1796.
14. Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(4):1734-1740.
15. Laurberg P, Andersen S, Carlé A, Karmisholt J, Knudsen N, Pedersen IB. The TSH upper reference limit: where are we at? *Nature Reviews Endocrinology*. 2011;7(4):232-239.
16. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *New England Journal of Medicine*. 1994;331(19):1249-1252.
17. Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. *Journal of Clinical Endocrinology & Metabolism*. 2014;99(7):2372-2382.
18. Wang W, Teng W, Shan Z, Wang S, Li J, Zhu L, et al. The prevalence of thyroid disorders during early pregnancy in China: the benefits of universal screening in the first trimester of pregnancy. *European Journal of Endocrinology*. 2011;164(2):263-268.
19. Zhurakulovna R. D. et al. Green Economy And Its Role In Preventing Air Pollution In Major Cities //Pedagogical Cluster-Journal of Pedagogical Developments. – 2024. – T. 2. – №. 2. – C. 478-484.
20. Zhurakulovna R. D. et al. ESTABLISHING THE RELATIONSHIP BETWEEN VARIOUS METASTATIC LUNG LESIONS WITH GENDER AND AGE //Web of Medicine: Journal of Medicine, Practice and Nursing. – 2024. – T. 2. – №. 2. – C. 104-107.

21. Zhurakulovna R. D., Abdurakhmanovna U. N. Current State of the Problem of Rationalization of Schoolchildren's Nutrition //Eurasian Medical Research Periodical. – 2023. – Т. 19. – С. 81-89.
22. Zhurakulovna R. D., Shomuratovna B. R., Narmuminovna G. G. HYGIENIC RECOMMENDATIONS FOR THE PREVENTION OF SCHOOL MYOPIA AND OTHER VISUAL IMPAIRMENTS IN CHILDREN OF PRIMARY SCHOOL AGE //American Journal of Interdisciplinary Research and Development. – 2022. – Т. 6. – С. 29-38.
23. Аскарова Н. К. и др. Клиническая характеристика хронических расстройств питания различного генеза у детей первых двух лет жизни //Научный аспект. – 2020. – Т. 2. – №. 1. – С. 259-264.
24. Аминов З. З. и др. Социальные аспекты и роль питания в стоматологическом здоровье детей и подростков //Academy. – 2019. – №. 10 (49). – С. 50-56.
25. Рахимова Д. Д., Шайхова Г. И. 7-17 YOSHLI MAKTAB OQUVCHILARINING JISMONIY RIVOJLANISHINI VAHOLASH //журнал репродуктивного здоровья и уро-нефрологических исследований. – 2022. – Т. 3. – №. 4.
26. Рахимова Д., Аскарова Н. Гиповитаминозы у военнослужащих //Общество и инновации. – 2021. – Т. 2. – №. 3/S. – С. 90-99.
27. Рахимова Д. Ж. и др. ОБОСНОВАНИЕ ЛЕЧЕНИЯ ПНЕВМОНИИ КОРОНАВИРУСНОЙ ЭТИОЛОГИИ (COVID-19) КОМБИНАЦИЕЙ ПУЛЬС ТЕРАПИИ С ИММУНОДЕПРЕССАНТАМИ //Re-health journal. – 2020. – №. 4 (8). – С. 59-64.
28. Рахимова Д. Ж. и др. Изменение состава микроэлементов у детей с хроническим расстройством питания первых двух лет жизни на фоне ОКИ //Научный аспект. – 2020. – Т. 2. – №. 1. – С. 252-258.